Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-R: Rollover Study of Opnurasib in Advanced Solid Tumors
NCT07468071Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Countries
- 10
01
Overview
A Phase 2 trial of opnurasib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Novartis. Started Jun 2026; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07468071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468071.